Reconstructed Skin Models for Atopic Dermatitis Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis in children are limited, with existing in vitro models failing to accurately replicate the complex pathophysiology of the condition, leading to a lack of effective emollients and formulations for restoring the skin barrier and modulating inflammatory responses.
Innovation Solution
Development of reconstructed skin models from children's skin samples that mimic the different phases of atopic dermatitis, allowing for the evaluation of cosmetic active agents and emollients in specific models reproducing barrier defects, inflammatory reactions, and bacterial infections, thereby identifying effective treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing in vitro models are used to evaluate treatments, then the evaluation process is simple, but the models fail to accurately replicate the complex pathophysiology of atopic dermatitis
Solution Approach 1:
The patent segments the complex pathophysiology of atopic dermatitis into distinct in vitro models, each reproducing specific phases or characteristics (barrier defects, inflammatory reactions, bacterial infections). This allows accurate replication of individual pathological aspects while maintaining manageable model complexity.
Solution Approach 2:
The patent creates a universal evaluation system using multiple in vitro models that can assess different aspects of atopic dermatitis pathophysiology. These models collectively provide comprehensive evaluation capabilities for barrier function, inflammation, and infection, making the system versatile for testing various treatment mechanisms.
2Measurement precision
If multiple in vitro models reproducing different phases of atopic dermatitis are developed, then the precision of treatment evaluation is improved, but the complexity of the evaluation system increases
Solution Approach 1:
The evaluation system is segmented into distinct in vitro models, each targeting specific pathological phases or characteristics of atopic dermatitis. This segmentation enables precise measurement of treatment effects on individual aspects (barrier repair, anti-inflammatory activity, antimicrobial effect) while keeping each model's complexity manageable.
Solution Approach 2:
The patent utilizes parameter changes in biological markers to precisely evaluate treatment efficacy. By measuring specific molecular and cellular parameters in each model, the system achieves high measurement precision for treatment evaluation despite the multi-model complexity.
3Reliability
If in vitro models accurately reproducing atopic dermatitis pathophysiology are created, then effective emollients and formulations can be identified, but the time and resources required for model development increase
Solution Approach 1:
The patent employs preliminary action by establishing standardized in vitro models that pre-reproduce known pathological features of atopic dermatitis. These pre-developed models with characterized biological markers provide a ready-to-use platform for evaluating treatments, reducing the time needed for new model development while maintaining high reliability.
Data Source
AI summary
The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is affected by atopic dermatitis. Such markers are particularly advantageous in that they allow the skin's response to atopic dermatitis to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of atopic dermatitis on a child's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.